Publications by authors named "Maisha Jabeen"

Macrolides reduce exacerbations when added to inhaled therapy in severe asthma. However, there is little published evidence for effectiveness in patients treated with biologics. We conducted a retrospective audit of all patients who started azithromycin while on biologics in our centre.

View Article and Find Full Text PDF
Article Synopsis
  • The study aimed to characterize the airway microbiome in severe asthma at the species level and examine how specific bacteria relate to mucosal immune responses, particularly in a subgroup of asthma known for low type-2 inflammation.
  • Researchers analyzed sputum and nasal samples from two cohorts of adults with severe asthma using advanced sequencing techniques and integrated data with clinical and protein assessments.
  • Findings indicated that a significant portion of severe asthma cases were dominated by specific pathogens like H. influenzae and M. catarrhalis, with distinct relationships observed between these bacteria and inflammatory responses in the airways.
View Article and Find Full Text PDF

Background: Asthma attacks are a common and important problem. Someone experiences an asthma attack in the United Kingdom every 10 seconds. Asthma attacks cause coughing, wheezing, breathlessness, and chest tightness and are highly stressful for patients.

View Article and Find Full Text PDF

Mucosal associated invariant T (MAIT) cells are innate-like T lymphocytes, strikingly enriched at mucosal surfaces and characterized by a semi-invariant αβ T cell receptor (TCR) recognizing microbial derived intermediates of riboflavin synthesis presented by the MHC-Ib molecule MR1. At barrier sites MAIT cells occupy a prime position for interaction with commensal microorganisms, comprising the microbiota. The microbiota is a rich source of riboflavin derived antigens required in early life to promote intra-thymic MAIT cell development and sustain a life-long population of tissue resident cells.

View Article and Find Full Text PDF

Asthma is a complex, heterogeneous condition that affects over 350 million people globally. It is characterised by bronchial hyperreactivity and airways inflammation. A subset display marked airway neutrophilia, associated with worse lung function, higher morbidity and poor response to treatment.

View Article and Find Full Text PDF

Previous metagenomic studies in asthma have been limited by inadequate sequencing depth for species-level bacterial identification and by heterogeneity in clinical phenotyping. We hypothesize that chronic bacterial airways infection is a key "treatable trait" whose prevalence, clinical phenotype and reliable biomarkers need definition. In this study, we have applied a method for Oxford Nanopore sequencing for the unbiased metagenomic characterization of severe asthma.

View Article and Find Full Text PDF

Reduction of the risk of asthma attacks is a major goal of current asthma management. We propose to derive a risk scale predicting asthma attacks based on the blood eosinophil count and exhaled nitric oxide (FeNO). Biomarker-stratified trial-level attack rates were extracted and pooled from the control arms of the Novel START, CAPTAIN, QUEST, Benralizumab Phase 2b, PATHWAY, STRATOS 1-2 and DREAM trials (n=3051).

View Article and Find Full Text PDF
Article Synopsis
  • The study investigated whether azithromycin could help reduce hospital admissions for patients with mild-to-moderate COVID-19, given its antibacterial and anti-inflammatory properties.
  • Conducted in the UK with 298 participants, the trial randomly assigned patients to receive either azithromycin plus standard care or standard care alone.
  • Results indicated that adding azithromycin did not significantly decrease the risk of hospital admission or death compared to standard care, with similar outcomes for both groups.
View Article and Find Full Text PDF

Background: Azithromycin is an orally active synthetic macrolide antibiotic with a wide range of anti-bacterial, anti-inflammatory and antiviral properties. It is a safe, inexpensive, generic licenced drug available worldwide and manufactured to scale and is a potential candidate therapy for pandemic coronavirus disease 2019 (COVID-19). Azithromycin was widely used to treat severe SARS-CoV and MERS-CoV, but to date, no randomised data are available in any coronavirus infections.

View Article and Find Full Text PDF

Mucosal-associated invariant T (MAIT) cells are MR1-restricted innate-like T cells conserved across mammalian species, including mice and humans. By sequencing RNA from sorted MR1-5-OP-RU tetramer cells derived from either human blood or murine lungs, we define the basic transcriptome of an activated MAIT cell in both species and demonstrate how this profile changes during the resolution of infection and during reinfection. We observe strong similarities between MAIT cells in humans and mice.

View Article and Find Full Text PDF

Non-typeable (NTHi) is a frequent cause of lower respiratory tract infection in people with chronic obstructive pulmonary disease (COPD). Pellino proteins are a family of E3 ubiquitin ligases that are critical regulators of TLR signaling and inflammation. The aim of this study was to identify a role for Pellino-1 in airway defense against NTHi in the context of COPD.

View Article and Find Full Text PDF
Article Synopsis
  • The study focuses on how neutrophils contribute to inflammation in humans by examining their recruitment and the production of the cytokine CXCL8.
  • In human subjects challenged with endotoxin, a significant local inflammatory response was observed, characterized by a notable increase in CXCL8 mRNA and neutrophil presence.
  • Neutrophils play a crucial role not only in the early release of cytokines like IL-1β but also in the clearance of CXCL8, which varies depending on the type of infection present.
View Article and Find Full Text PDF